Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 100
  • Home
  • Print this page
  • Email this page
This article has been cited by
1Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review
Taylor Halsey,Gabriel Ologun,Jennifer Wargo,Robert R. Jenq
Seminars in Hematology.2020;57(1)13
[DOI]
2Atezolizumab-induced myositis and myocarditis in a patient with metastatic urothelial carcinoma
Mary Sessums,Siva Yarrarapu,Pramod K Guru,Devang K Sanghavi
BMJ Case Reports.2020;13(12)e236357
[DOI]
3

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date

Iris Y Sheng,Moshe C Ornstein
Cancer Management and Research.2020;Volume 12(12)4871
[DOI]
4Classical Examples of the Concept of the ASIA Syndrome
Vânia Borba,Anna Malkova,Natalia Basantsova,Gilad Halpert,Laura Andreoli,Angela Tincani,Howard Amital,Yehuda Shoenfeld
Biomolecules.2020;10(10)1436
[DOI]
5Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Silvia Vivarelli,Luca Falzone,Caterina Maria Grillo,Giuseppa Scandurra,Francesco Torino,Massimo Libra
Cancers.2020;12(8)2237
[DOI]
6PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
John Turchini,Loretta Sioson,Adele Clarkson,Amy Sheen,Anthony J. Gill
Endocrine Pathology.2021;12(8)2237
[DOI]
7Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities
Pak Yui Fong,Shing Chuen Chow,Bernard Ming Hong Kwong,Charlene Cheuk Lam Lau,Christy Yik Ching Lau,Athena Hoi Ting Lee,Ha Ying Nip,Cheuk Yin Wong,Benedict Tsz Hin Yan,Ho Yin Chung
Journal of Clinical Rheumatology and Immunology.2020;20(01)25
[DOI]
8Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non–Small Cell Lung Cancer
Ninh M. La-Beck,Dung T. Nguyen,Alex D. Le,Saeed K. Alzghari,Saralinh T. Trinh
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2020;40(3)239
[DOI]
9Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society
Takeshi Johkoh,Kyung Soo Lee,Mizuki Nishino,William D. Travis,Jay H. Ryu,Ho Yun Lee,Christopher J. Ryerson,Tomás Franquet,Alexander A. Bankier,Kevin K. Brown,Jin Mo Goo,Hans-Ulrich Kauczor,David A. Lynch,Andrew G. Nicholson,Luca Richeldi,Cornelia M. Schaefer-Prokop,Johny Verschakelen,Suhail Raoof,Geoffrey D. Rubin,Charles Powell,Yoshikazu Inoue,Hiroto Hatabu
Radiology.2021;298(3)550
[DOI]
10Endocrine complications of immunotherapies: a review
Rosie Hattersley,Melanie Nana,Andrew J Lansdown
Clinical Medicine.2021;21(2)e212
[DOI]
11The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events
Bradley D. Menz,Jacinta L. Johnson,Davina F. Gillard,William Chong,Michael B. Ward
Journal of Pharmacy Practice.2021;34(3)386
[DOI]
12Immune-Mediated Toxic Epidermal Necrolysis
Dinesh Keerty,Viktoriya Koverzhenko,Dalila Belinc,Katie LaPorta,Elizabeth Haynes
Cureus.2020;34(3)386
[DOI]
13Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient
Dejan Vidovic,Gordon A. Simms,Sylvia Pasternak,Mark Walsh,Kevork Peltekian,John Stein,Lucy K. Helyer,Carman A. Giacomantonio
Frontiers in Immunology.2021;12(3)386
[DOI]
14Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces
Maria V Deligiorgi,Charis Liapi,Dimitrios T Trafalis
Expert Opinion on Biological Therapy.2021;12(3)1
[DOI]
15A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer
Kyung Woo Kim,Sentaro Kusuhara,Motoko Tachihara,Chihiro Mimura,Wataru Matsumiya,Makoto Nakamura
American Journal of Ophthalmology Case Reports.2021;22(3)101072
[DOI]
16Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs
Tyler C. Vandivort,David B. Horton,Steven B. Johnson
Journal of Clinical and Translational Science.2020;4(6)547
[DOI]
17Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
Ronald Anderson,Annette J. Theron,Bernardo L. Rapoport
Frontiers in Immunology.2019;10(6)547
[DOI]
18Atypical extended immune-related neutropenia in patient treated with pembrolizumab
Pierre-Antoine Laurain,Térence Landrin,Sami Souidi,Philippe Beuzeboc,Florian Scotté
European Journal of Cancer.2020;130(6)269
[DOI]
19Angioedema late in the course of adjuvant nivolumab therapy for melanoma
Atul Ratra,Constantin A Dasanu
Journal of Oncology Pharmacy Practice.2020;26(4)1019
[DOI]
20Angioedema late in the course of adjuvant nivolumab therapy for melanoma
Aanika Balaji,Bairavi Shankar,Jarushka Naidoo
Journal of Oncology Pharmacy Practice.2021;26(4)191
[DOI]
21Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers
Tomomi W Nobashi,Yuko Nishimoto,Yujiro Kawata,Hidetaka Yutani,Masaki Nakamura,Yuichi Tsuji,Atsushi Yoshida,Akihiko Sugimoto,Takayuki Yamamoto,Israt S Alam,Satoshi Noma
The British Journal of Radiology.2020;93(1115)20200409
[DOI]
22Management of immune checkpoint inhibitor-related rheumatic adverse events
Jiaxin Zhou,Hanping Wang,Xiaoxiao Guo,Qian Wang,Lian Duan,Xiaoyan Si,Li Zhang,Xiaowei Liu,Yue Li,Wen Zhang,Li Zhang
Thoracic Cancer.2020;11(1)198
[DOI]
23Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
Dristhi Ragoonanan,Sajad J. Khazal,Hisham Abdel-Azim,David McCall,Branko Cuglievan,Francesco Paolo Tambaro,Ali Haider Ahmad,Courtney M. Rowan,Cristina Gutierrez,Keri Schadler,Shulin Li,Matteo Di Nardo,Linda Chi,Alison M. Gulbis,Basirat Shoberu,Maria E. Mireles,Jennifer McArthur,Neena Kapoor,Jeffrey Miller,Julie C. Fitzgerald,Priti Tewari,Demetrios Petropoulos,Jonathan B. Gill,Christine N. Duncan,Leslie E. Lehmann,Sangeeta Hingorani,Joseph R. Angelo,Rita D. Swinford,Marie E. Steiner,Fiorela N. Hernandez Tejada,Paul L. Martin,Jeffery Auletta,Sung Won Choi,Rajinder Bajwa,Natalie Dailey Garnes,Partow Kebriaei,Katayoun Rezvani,William G. Wierda,Sattva S. Neelapu,Elizabeth J. Shpall,Selim Corbacioglu,Kris M. Mahadeo
Nature Reviews Clinical Oncology.2021;11(1)198
[DOI]
24The Increasing Role of Immunotherapy in the Management of Solid Cancers and its impact on Caribbean health services resources and provision.
Jo-Anne Kissoon
Caribbean Medical Journal.2020;11(1)198
[DOI]
25Budosenid Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report
El Ali Ziad,Verset Laurine
Clinical Oncology and Research.2019;11(1)1
[DOI]
26Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis
Andrea Pagan,Yadis M Arroyo-Martinez,Ankita Tandon,Carlos Bertran-Rodriguez,Jeffrey Gill
Cureus.2020;11(1)1
[DOI]
27ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Naga P. Chalasani,Haripriya Maddur,Mark W. Russo,Robert J. Wong,K. Rajender Reddy
American Journal of Gastroenterology.2021;116(5)878
[DOI]
28Durvalumab in cancer medicine: a comprehensive review
Juliana Alvarez-Argote,Constantin A. Dasanu
Expert Opinion on Biological Therapy.2019;19(9)927
[DOI]
29Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors
Lillian Sun,Joshua Arbesman,Melissa Piliang
Archives of Dermatological Research.2021;313(1)1
[DOI]
30Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Massimo Ralli,Andrea Botticelli,Irene Claudia Visconti,Diletta Angeletti,Marco Fiore,Paolo Marchetti,Alessandro Lambiase,Marco de Vincentiis,Antonio Greco
Journal of Immunology Research.2020;2020(1)1
[DOI]
31Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors
Takeshi Johkoh,Kyung Soo Lee,Mizuki Nishino,William D. Travis,Jay H. Ryu,Ho Yun Lee,Christopher J. Ryerson,Tomás Franquet,Alexander A. Bankier,Kevin K. Brown,Jin Mo Goo,Hans-Ulrich Kauczor,David A. Lynch,Andrew G. Nicholson,Luca Richeldi,Cornelia M. Schaefer-Prokop,Johny Verschakelen,Suhail Raoof,Geoffrey D. Rubin,Charles Powell,Yoshikazu Inoue,Hiroto Hatabu
Chest.2021;159(3)1107
[DOI]
32Diabetic Ketoacidosis: An Adverse Reaction to Immunotherapy
Dinesh Keerty,Manoj Das,Julie Hallanger-Johnson,Elizabeth Haynes
Cureus.2020;159(3)1107
[DOI]
33Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin’s lymphoma
Thai Dang,Samir Macwan,Constantin A Dasanu
Journal of Oncology Pharmacy Practice.2020;159(3)107815522097679
[DOI]
34Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use
Rebecca N. Jerome,Meghan Morrison Joly,Nan Kennedy,Jana K. Shirey-Rice,Dan M. Roden,Gordon R. Bernard,Kenneth J. Holroyd,Joshua C. Denny,Jill M. Pulley
Drug Safety.2020;43(6)567
[DOI]
35Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy
Maria V. Deligiorgi,Gerasimos Siasos,Chrysovalantis Vergadis,Dimitrios T. Trafalis
International Immunopharmacology.2020;83(6)106427
[DOI]
36Cancer immunotherapy–related adverse events: causes and challenges
Ada G. Blidner,Jennifer Choi,Tim Cooksley,Michael Dougan,Ilya Glezerman,Pamela Ginex,Monica Girotra,Dipti Gupta,Douglas Johnson,Vickie R. Shannon,Maria Suarez-Almazor,Bernardo L. Rapoport,Ronald Anderson
Supportive Care in Cancer.2020;28(12)6111
[DOI]
37Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event
Maria V. Deligiorgi,Dimitrios T. Trafalis
International Immunopharmacology.2020;89(12)107050
[DOI]
38Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
Omid Kooshkaki,Afshin Derakhshani,Negar Hosseinkhani,Mitra Torabi,Sahar Safaei,Oronzo Brunetti,Vito Racanelli,Nicola Silvestris,Behzad Baradaran
International Journal of Molecular Sciences.2020;21(12)4427
[DOI]
39Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gall Bladder With a Mass
Nayson L Fernandes,Soujanya Sodavarapu,Sukhmine Nedopil,Nikita Mohapatra,Dinesh Vyas
Cureus.2020;21(12)4427
[DOI]
40Cardiotoxicity of immune checkpoint inhibitors: An updated review
Soheil Behravesh,Navid Shomali,Gholamreza Rezaei Danbaran,Saeed Aslani,Maryam Hemmatzadeh,Ramin Hosseinzadeh,Arezoo Gowhari-Shabgah,Hamed Mohammadi
Biotechnology and Applied Biochemistry.2020;21(12)4427
[DOI]
41Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma
Alberto Martini,Giuseppe Fallara,Francesco Pellegrino,Giuseppe Ottone Cirulli,Alessandro Larcher,Andrea Necchi,Francesco Montorsi,Umberto Capitanio
World Journal of Urology.2021;39(5)1369
[DOI]
42Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells
Rhiane Moody,Kirsty Wilson,Anthony Jaworowski,Magdalena Plebanski
Cancers.2020;12(3)673
[DOI]
43Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians
Maria V Deligiorgi,Mihalis I Panayiotidis,Dimitrios T Trafalis
Immunotherapy.2020;12(7)481
[DOI]
44Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma
Katarina Hradska,Michal Kascak,Roman Hajek,Tomas Jelinek
Expert Review of Hematology.2020;13(4)375
[DOI]
45The role of combination chemo-immunotherapy in advanced non-small cell lung cancer
Danilo Rocco,Luigi Della Gravara,Ciro Battiloro,Cesare Gridelli
Expert Review of Anticancer Therapy.2019;19(7)561
[DOI]
Feedback
Subscribe

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal